Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nxera Pharma
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
October 22, 2026
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
October 14, 2026
Nxera Announces Successful Resolution of miniG Patent Infringement Action
October 1, 2026
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
September 3, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer’s Cognition
August 26, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
August 7, 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
May 11, 2026
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
May 8, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
May 1, 2026